Delisting Determination,The Nasdaq Stock Market, LLC,
February 23, 2016, Skystar Bio-Pharmaceutical Company.
The Nasdaq Stock Market, Inc. (the Exchange) has determined to
remove from listing the common stock of
Skystar Bio-Pharmaceutical Company
(the Company), effective at the opening of the trading
session on March 4, 2016. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rules 5250(c)(1), 5250(b)(1), and 5100.
The Company was notified
of the Staffs determination on October 10, 2015.  The
Company appealed the determination to a Hearing Panel.
Upon review of the information provided by the Company,
the Panel issued a decision dated December 17, 2015, denying
the Company continued listing and notified the Company
that trading in the Companys
securities would be suspended on December 21, 2015.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on February 1, 2016.